Study type: Human research · Status: Evidence verified by machine against declared source
Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics
Journal of Neuroendocrinology · 2012
Study scale: During the period 1980–2012, over 3000 samples of OT and AVP agonists and antagonists from the Manning laboratory have been and continue to be donated as research tools to over 700 investigators (some multiple times) in the USA and worldwide for their own independent studies.
Abstract only: Open source record
Product or molecular entity relationships
- Oxytocin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Public plain-language summary
Some fields are not published, because the text held for them did not answer their heading. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
The central effects of OT continue to be the focus of intense investigative scrutiny in animals (24–28) and in humans (29–35), as a possible therapeutic agent for the treatment of autism and other anxiety disorders.
Study design
A promising OT antagonist, Retosiban, developed at Glaxo SmithKline is currently in a Phase II clinical trial for the prevention of premature labour.
Participants or experimental system
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Study scale
During the period 1980–2012, over 3000 samples of OT and AVP agonists and antagonists from the Manning laboratory have been and continue to be donated as research tools to over 700 investigators (some multiple times) in the USA and worldwide for their own independent studies.
Intervention or exposure
To date, only two nonpeptides, the V2/V1a antagonist, conivaptan and the V2 antagonist tolvaptan have received Food and Drug Administration approval for clinical use.
Comparator
We also review the merits of peptide versus nonpeptide AVP and OT agonists and antagonists as: (i) research tools and (ii) therapeutic agents.
Outcomes examined
The recently reported (38) highly selective OT analogue FE 202767 (peptide 5) has not been evaluated in standard rat bioassays.
Key findings
Many of these ligands have found widespread use as pharmacological tools for studies on the peripheral and central effects of OT and AVP.
Limitations and uncertainty
From all the in vitro and in vivo pharmacological studies carried out on OT and VP agonists and antagonists, three intriguing features have emerged; namely: (i) lack of receptor selectivity; (ii) species differences; and (iii) in vitro in vivo difference.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.